• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Helix Acquisition Corp. II

    11/14/24 1:22:40 PM ET
    $HLXB
    Get the next $HLXB alert in real time by email
    SC 13G 1 hlxb13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) HELIX ACQUISITION CORP II (Name of Issuer) COMMON STOCK (Title of Class of Securities) G4444H101 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,127,598 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,127,598 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,127,598 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 6.0% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: HELIX ACQUISITION CORP II Item 1(b) Address of Issuer's Principal Executive Offices: C/O CORMORANT ASSET MANAGEMENT LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON, MA 02116 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: G4444H101 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024
    Get the next $HLXB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HLXB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

      Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

      7/11/25 7:43:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

      Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci

      2/28/25 7:49:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HLXB
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Helix Acquisition Corp. II

      SCHEDULE 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      7/24/25 9:05:28 PM ET
      $HLXB
    • SEC Form 424B3 filed by Helix Acquisition Corp. II

      424B3 - Helix Acquisition Corp. II (0001869105) (Filer)

      7/21/25 9:05:22 PM ET
      $HLXB
    • SEC Form 425 filed by Helix Acquisition Corp. II

      425 - Helix Acquisition Corp. II (0001869105) (Subject)

      7/21/25 8:10:22 AM ET
      $HLXB

    $HLXB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Holman Albert A Iii

      3 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/11/25 5:16:28 PM ET
      $HLXB
    • SEC Form 4 filed by Director Helix Holdings Ii Llc

      4 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/10/25 5:07:46 PM ET
      $HLXB
    • SEC Form 4 filed by CEO and Chairperson Chen Bihua

      4 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/10/25 5:06:42 PM ET
      $HLXB

    $HLXB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      11/14/24 1:22:40 PM ET
      $HLXB
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      2/23/24 4:30:20 PM ET
      $HLXB
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      2/23/24 4:01:43 PM ET
      $HLXB